# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-19-054172
Filing Date
2019-10-15
Accepted
2019-10-15 16:30:25
Documents
6
Period of Report
2019-12-09
Effectiveness Date
2019-10-15

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tv530721-def14a.htm | DEF 14A | 179022
2 | GRAPHIC | lg_protalix.jpg | GRAPHIC | 5865
3 | GRAPHIC | pc_tv530721proxy01-lr.jpg | GRAPHIC | 241948
4 | GRAPHIC | pc_tv530721proxy02-lr.jpg | GRAPHIC | 320119
5 | GRAPHIC | sg_drorbashan.jpg | GRAPHIC | 4652
6 | GRAPHIC | sg_eyalrubin-bw.jpg | GRAPHIC | 168468
| Complete submission text file | 0001104659-19-054172.txt |  | 1168747

Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 191151250
SIC: 2836 Biological Products, (No Diagnostic Substances)